We are pleased to inform our valued patients about the introduction of Daxxify at the New York Cosmetic Skin & Laser Surgery Center. This advanced anti-aging treatment, built upon cutting-edge peptide technology, has received FDA approval for its remarkable ability to reduce the appearance of facial wrinkles. This newer neurotoxin is similar to Botox and can be used in similar areas to botox. Typical areas of wrinkles which can be treated with Daxxify include frown lines or eleven lines, crows feet, forehead lines, upper lip lines, bunny lines in the nose, and platysma bands which wrinkles the neck.
Under the guidance of Dr. Cameron Rokhsar, MD, a double board certified dermatologist and surgeon, our facility is at the forefront of offering Daxxify to the New York community. Its effects have been observed by some to last up to 6 months.
Clinical trials have showcased Daxxify’s effectiveness in treating moderate to severe frown lines among adults. Daxxify’s longevity, which possibly extends up to two months longer than neurotoxin treatments, like Botox, Xeomin or Dysport gives patients yet another therapeutics to improve wrinkles and signs of aging.
Both Daxxify and Botox function as acetylcholine release inhibitors and neuromuscular blocking agents. However, Daxxify integrates superior peptide exchange technology, enhancing its binding affinity to receptors, potentially resulting in sustained outcomes. It’s worth noting that Daxxify is the only neuromodulator without human serum albumin, eliminating potential allergens found in human blood or animal sources. In comparison to Botox, which lasts 3-4 months, Daxxify may offer up to 5-6 months of extended therapeutic benefits. However this requires a higher dosage of neurotoxin compared to Botox dosing.
Daxxify’s utility extends beyond cosmetic applications. It has been identified as an effective treatment for various medical conditions, including neck spasms, excessive sweating, overactive bladder, and strabismus (lazy eye). Clinical evaluations underscore its excellent safety profile, with no significant treatment-associated complications reported.
Dr. Rokhsar can use Daxxify to treat many areas of wrinkles on the face. These include wrinkles on the forehead, frown lines, crows feet, wrinkles around the mouth, wrinkles on the nose or bunny lines, and neck lines created by platysma.
Daxxify is the newest FDA approved neurotoxin that is available in the US since January 2023. Daxxify works very similarly to other currently available neurotoxins such as Botox Dysport Juveau and Xeomin. Daxxify’s mechanism of action is also very similar to the other available neurotoxins. It works by disrupting the signal from the nerve to the muscles which decreases muscle movement in specific areas of the face, thereby decreasing lines and wrinkles.
It’s actually controversial how long Daxxify truly lasts. The company claims that Daxxify lasts 5-6 months when administered in the glabella or frown lines, however what the company fails to tell physicians and patients is that the studies that were done in the frown complex/ eleven lines were done using double the dose as other equivalent neurotoxins. This may result in the possible increased longevity in the glabella area, however doubling the dose with other neurotoxins will give similar results. The caveat is that doubling the dose can only be used safely only in the glabella for natural results. If a double dose is attempted in other commonly placed neurotoxin areas such as crows feet and forehead, then drooping, frozenness and heaviness of the eyelids can occur, causing unnatural results.
Daxxify kicks in 3-5 days after injection, which is very similar to Botox, Dysport, and Juveau. All of these neurotoxins have similar mechanisms of action with similar onsets of action.
Daxxify and Botox are both FDA approved neurotoxins available for treatment of patients in the United States. They are made by two different companies, Botox by Allergan, and Daxxify by Revance. Botox was the first FDA approved neurotoxin available in the United States. It has been FDA approved for cosmetic reasons in the US since 2002. Daxxify is the newest FDA approved neurotoxin, having been available to physicians and patients in the US since January 2023. The experience of physicians and patients with Botox is a lot more vast, as tens of millions of patients around the world have been treated safely and effectively throughout the past two decades. Clinical experience with Daxxify is much more limited, having been around for only one year in the US. Daxxify claims that their toxin may last 1-2 months longer than Botox, however, this claim is controversial due to the fact that the studies that these assertions stem from have been done utilizing a double dose technique which if employed with Botox, would give similar longevity results.
January 2023 in the United States
Upper East Side Manhattan Office
121 East 60th Street, Suite 8AB New York, NY 10022
Long Island Office
901 Stewart Ave, Suite 240, Garden City, NY 11530